loading
Tenax Therapeutics Inc stock is traded at $6.30, with a volume of 4,768. It is down -0.94% in the last 24 hours and up +5.53% over the past month.
See More
Previous Close:
$6.36
Open:
$6.48
24h Volume:
4,768
Relative Volume:
0.11
Market Cap:
$25.22M
Revenue:
-
Net Income/Loss:
$-14.56M
P/E Ratio:
-0.3746
EPS:
-16.82
Net Cash Flow:
$-12.46M
1W Performance:
+2.74%
1M Performance:
+5.53%
6M Performance:
+88.62%
1Y Performance:
+62.79%
1-Day Range:
Value
$6.26
$6.48
1-Week Range:
Value
$6.00
$6.76
52-Week Range:
Value
$2.77
$7.89

Tenax Therapeutics Inc Stock (TENX) Company Profile

Name
Name
Tenax Therapeutics Inc
Name
Phone
919-855-2100
Name
Address
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Name
Employee
0
Name
Twitter
@TenaxThera
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
TENX's Discussions on Twitter

Compare TENX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TENX
Tenax Therapeutics Inc
6.30 25.22M 0 -14.56M -12.46M -16.82
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-24-24 Initiated Leerink Partners Outperform
Oct-14-24 Initiated Guggenheim Buy
Sep-30-24 Initiated William Blair Outperform
May-18-17 Upgrade Ladenburg Thalmann Neutral → Buy
Dec-16-14 Initiated MLV & Co Buy
Nov-18-14 Initiated WallachBeth Buy
View All

Tenax Therapeutics Inc Stock (TENX) Latest News

pulisher
Mar 31, 2025

Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times

Mar 31, 2025
pulisher
Mar 31, 2025

Exclusive: Tenax Leadership Team to Unveil Latest Phase 3 Progress at Major Healthcare Conference - Stock Titan

Mar 31, 2025
pulisher
Mar 31, 2025

What is Leerink Partnrs’ Forecast for TENX Q1 Earnings? - Defense World

Mar 31, 2025
pulisher
Mar 29, 2025

Equities Analysts Offer Predictions for TENX Q1 Earnings - Defense World

Mar 29, 2025
pulisher
Mar 29, 2025

Q1 Earnings Estimate for TENX Issued By William Blair - Defense World

Mar 29, 2025
pulisher
Mar 29, 2025

Tenax Therapeutics (NASDAQ:TENX) Earns Sell Rating from Analysts at StockNews.com - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

Research Analysts Set Expectations for TENX Q1 Earnings - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

When (TENX) Moves Investors should Listen - news.stocktradersdaily.com

Mar 27, 2025
pulisher
Mar 26, 2025

Tenax Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 26, 2025
pulisher
Mar 25, 2025

Tenax Therapeutics: Q4 Earnings Snapshot - CT Insider

Mar 25, 2025
pulisher
Mar 25, 2025

Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides - Bluefield Daily Telegraph

Mar 25, 2025
pulisher
Mar 25, 2025

Tenax Raises Massive $125M War Chest: Phase 3 Heart Failure Drug Trial Gets Major Boost - Stock Titan

Mar 25, 2025
pulisher
Mar 24, 2025

Tenax Therapeutics Inc expected to post a loss of 42 cents a shareEarnings Preview - TradingView

Mar 24, 2025
pulisher
Mar 21, 2025

Tenax Therapeutics (NASDAQ:TENX) Now Covered by Analysts at StockNews.com - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

Tenax Therapeutics (TENX) to Release Earnings on Thursday - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Plastic Fencing Market to be Driven by Growing Residential and Commercial Construction Activities, Exclusive Research by The Insight Partners - GlobeNewswire Inc.

Mar 19, 2025
pulisher
Mar 11, 2025

Tenax Therapeutics (NASDAQ:TENX) Given “Outperform” Rating at William Blair - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

Promising Developments and Financial Backing Drive Buy Rating for Tenax Therapeutics - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

What is Roth Capital’s Estimate for TENX FY2024 Earnings? - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

Roth Capital Predicts Weaker Earnings for Tenax Therapeutics - Defense World

Mar 09, 2025
pulisher
Mar 06, 2025

(TENX) Proactive Strategies - news.stocktradersdaily.com

Mar 06, 2025
pulisher
Mar 05, 2025

Tenax Therapeutics Announces $25 Million Private Placement - GlobeNewswire

Mar 05, 2025
pulisher
Mar 05, 2025

Tenax Therapeutics announces $25M private placement - MSN

Mar 05, 2025
pulisher
Mar 05, 2025

Tenax Therapeutics prices 378,346 shares at $6.04 in private placement - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Tenax Therapeutics expands Phase 3 LEVEL program for TNX-103 - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Tenax Therapeutics secures $25 million in private placement - Investing.com India

Mar 05, 2025
pulisher
Mar 05, 2025

Tenax Therapeutics Announces $25 Million Private Placement -March 05, 2025 at 08:54 am EST - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

Tenax Therapeutics secures $25 million in private placement By Investing.com - Investing.com UK

Mar 05, 2025
pulisher
Mar 05, 2025

Tenax Therapeutics Secures $25 Million From RTW Investments For Phase 3 Clinical Trials - StockTitan

Mar 05, 2025
pulisher
Mar 05, 2025

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing - GlobeNewswire

Mar 05, 2025
pulisher
Mar 05, 2025

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF - Yahoo Finance

Mar 05, 2025
pulisher
Mar 05, 2025

Bristol Myers’ MyoKardia unit ends work with Fulcrum; ALX discloses layoffs - Endpoints News

Mar 05, 2025
pulisher
Mar 03, 2025

Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference - The Manila Times

Mar 03, 2025
pulisher
Mar 03, 2025

Can Tenax Therapeutics' Conference Appearance Signal New Cardiovascular Treatment Progress? - StockTitan

Mar 03, 2025
pulisher
Feb 26, 2025

Investor Network Invites You to the Tenax Therapeutics Fiscal Year 2016 Business Review and Update Conference Call and Webcast on Tuesday, March 21, 2017 - ACCESS Newswire

Feb 26, 2025
pulisher
Feb 16, 2025

Tenax Therapeutics appoints new VP of Clinical Operations - MSN

Feb 16, 2025
pulisher
Feb 14, 2025

Tenax Therapeutics (NASDAQ:TENX) Shares Pass Above 200 Day Moving Average – What’s Next? - Defense World

Feb 14, 2025
pulisher
Feb 13, 2025

How the (TENX) price action is used to our Advantage - Stock Traders Daily

Feb 13, 2025
pulisher
Feb 06, 2025

Leerink Partnrs Weighs in on TENX FY2029 Earnings - Defense World

Feb 06, 2025
pulisher
Feb 05, 2025

David Risinger Recommends Buy for Tenax Therapeutics Amid Promising Phase 3 Trials and Growth Potential - TipRanks

Feb 05, 2025
pulisher
Feb 04, 2025

Tenax Therapeutics (NASDAQ:TENX) Share Price Passes Above 200-Day Moving Average – What’s Next? - Defense World

Feb 04, 2025
pulisher
Feb 01, 2025

Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - GlobeNewswire

Feb 01, 2025
pulisher
Jan 31, 2025

Exclusive: Tenax CEO to Reveal Latest Cardiovascular Drug Pipeline Updates at Major Biotech Conference - StockTitan

Jan 31, 2025
pulisher
Jan 24, 2025

Tenax Therapeutics (NASDAQ:TENX) Stock Price Crosses Above 200 Day Moving Average – What’s Next? - Defense World

Jan 24, 2025
pulisher
Jan 22, 2025

Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations - The Manila Times

Jan 22, 2025

Tenax Therapeutics Inc Stock (TENX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
Cap:     |  Volume (24h):